Cargando…
Management of secondary hyperparathyroidism: practice patterns and outcomes of cinacalcet treatment with or without active vitamin D in Austria and Switzerland – the observational TRANSIT Study
Secondary hyperparathyroidism is a complex disorder requiring an individualized multicomponent treatment approach. This study was conducted to identify treatment combinations used in clinical practice in Austria and Switzerland and the potential to control this disorder. A total of 333 adult hemodia...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5429358/ https://www.ncbi.nlm.nih.gov/pubmed/28091752 http://dx.doi.org/10.1007/s00508-016-1153-z |
_version_ | 1783235997512761344 |
---|---|
author | Pronai, Wolfgang Rosenkranz, Alexander R. Bock, Andreas Klauser-Braun, Renate Jäger, Christine Pendl, Gunther Hemetsberger, Margit Lhotta, Karl |
author_facet | Pronai, Wolfgang Rosenkranz, Alexander R. Bock, Andreas Klauser-Braun, Renate Jäger, Christine Pendl, Gunther Hemetsberger, Margit Lhotta, Karl |
author_sort | Pronai, Wolfgang |
collection | PubMed |
description | Secondary hyperparathyroidism is a complex disorder requiring an individualized multicomponent treatment approach. This study was conducted to identify treatment combinations used in clinical practice in Austria and Switzerland and the potential to control this disorder. A total of 333 adult hemodialysis and peritoneal dialysis patients were analyzed. All patients received conventional care prior to initiation of a cinacalcet-based regimen. During the study, treatment components, e.g. cinacalcet, active vitamin D analogues and phosphate binders, were adapted to individual patient requirements and treatment dynamics were documented. Overall, the mean intact parathyroid hormone (iPTH) increased from 64.2 pmol/l to 79.6 pmol/l under conventional therapy and decreased after cinacalcet initiation to 44.0 pmol/l after 12 months (mean decrease between baseline and 12 months −45%). Calcium remained within the normal range throughout the study and phosphorus ranged around the upper limit of normal. The Kidney Disease: Improving Global Outcomes (KDIGO) target achievement for iPTH increased from 44.5% of patients at baseline to 65.7% at 12 months, corrected calcium from 58.9% to 51.9% and phosphorus from 18.4% to 24.4%. On average, approximately 30% of patients adapted their regimen from one observation period to the next. The reasons for changing a given regimen were to attain or maintain any of the bone mineral markers within recommended targets and to avoid developments to extreme values. Some regional differences in practice patterns were identified. No new safety signals emerged. In conclusion, cinacalcet appears to be a necessary treatment component to achieve recommended targets. The detailed composition of the treatment mix should be adapted to patient requirements and reassessed on a regular basis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi: 10.1007/s00508-016-1153-z) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5429358 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer Vienna |
record_format | MEDLINE/PubMed |
spelling | pubmed-54293582017-05-30 Management of secondary hyperparathyroidism: practice patterns and outcomes of cinacalcet treatment with or without active vitamin D in Austria and Switzerland – the observational TRANSIT Study Pronai, Wolfgang Rosenkranz, Alexander R. Bock, Andreas Klauser-Braun, Renate Jäger, Christine Pendl, Gunther Hemetsberger, Margit Lhotta, Karl Wien Klin Wochenschr Original Article Secondary hyperparathyroidism is a complex disorder requiring an individualized multicomponent treatment approach. This study was conducted to identify treatment combinations used in clinical practice in Austria and Switzerland and the potential to control this disorder. A total of 333 adult hemodialysis and peritoneal dialysis patients were analyzed. All patients received conventional care prior to initiation of a cinacalcet-based regimen. During the study, treatment components, e.g. cinacalcet, active vitamin D analogues and phosphate binders, were adapted to individual patient requirements and treatment dynamics were documented. Overall, the mean intact parathyroid hormone (iPTH) increased from 64.2 pmol/l to 79.6 pmol/l under conventional therapy and decreased after cinacalcet initiation to 44.0 pmol/l after 12 months (mean decrease between baseline and 12 months −45%). Calcium remained within the normal range throughout the study and phosphorus ranged around the upper limit of normal. The Kidney Disease: Improving Global Outcomes (KDIGO) target achievement for iPTH increased from 44.5% of patients at baseline to 65.7% at 12 months, corrected calcium from 58.9% to 51.9% and phosphorus from 18.4% to 24.4%. On average, approximately 30% of patients adapted their regimen from one observation period to the next. The reasons for changing a given regimen were to attain or maintain any of the bone mineral markers within recommended targets and to avoid developments to extreme values. Some regional differences in practice patterns were identified. No new safety signals emerged. In conclusion, cinacalcet appears to be a necessary treatment component to achieve recommended targets. The detailed composition of the treatment mix should be adapted to patient requirements and reassessed on a regular basis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi: 10.1007/s00508-016-1153-z) contains supplementary material, which is available to authorized users. Springer Vienna 2017-01-13 2017 /pmc/articles/PMC5429358/ /pubmed/28091752 http://dx.doi.org/10.1007/s00508-016-1153-z Text en © The Author(s) 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Pronai, Wolfgang Rosenkranz, Alexander R. Bock, Andreas Klauser-Braun, Renate Jäger, Christine Pendl, Gunther Hemetsberger, Margit Lhotta, Karl Management of secondary hyperparathyroidism: practice patterns and outcomes of cinacalcet treatment with or without active vitamin D in Austria and Switzerland – the observational TRANSIT Study |
title | Management of secondary hyperparathyroidism: practice patterns and outcomes of cinacalcet treatment with or without active vitamin D in Austria and Switzerland – the observational TRANSIT Study |
title_full | Management of secondary hyperparathyroidism: practice patterns and outcomes of cinacalcet treatment with or without active vitamin D in Austria and Switzerland – the observational TRANSIT Study |
title_fullStr | Management of secondary hyperparathyroidism: practice patterns and outcomes of cinacalcet treatment with or without active vitamin D in Austria and Switzerland – the observational TRANSIT Study |
title_full_unstemmed | Management of secondary hyperparathyroidism: practice patterns and outcomes of cinacalcet treatment with or without active vitamin D in Austria and Switzerland – the observational TRANSIT Study |
title_short | Management of secondary hyperparathyroidism: practice patterns and outcomes of cinacalcet treatment with or without active vitamin D in Austria and Switzerland – the observational TRANSIT Study |
title_sort | management of secondary hyperparathyroidism: practice patterns and outcomes of cinacalcet treatment with or without active vitamin d in austria and switzerland – the observational transit study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5429358/ https://www.ncbi.nlm.nih.gov/pubmed/28091752 http://dx.doi.org/10.1007/s00508-016-1153-z |
work_keys_str_mv | AT pronaiwolfgang managementofsecondaryhyperparathyroidismpracticepatternsandoutcomesofcinacalcettreatmentwithorwithoutactivevitamindinaustriaandswitzerlandtheobservationaltransitstudy AT rosenkranzalexanderr managementofsecondaryhyperparathyroidismpracticepatternsandoutcomesofcinacalcettreatmentwithorwithoutactivevitamindinaustriaandswitzerlandtheobservationaltransitstudy AT bockandreas managementofsecondaryhyperparathyroidismpracticepatternsandoutcomesofcinacalcettreatmentwithorwithoutactivevitamindinaustriaandswitzerlandtheobservationaltransitstudy AT klauserbraunrenate managementofsecondaryhyperparathyroidismpracticepatternsandoutcomesofcinacalcettreatmentwithorwithoutactivevitamindinaustriaandswitzerlandtheobservationaltransitstudy AT jagerchristine managementofsecondaryhyperparathyroidismpracticepatternsandoutcomesofcinacalcettreatmentwithorwithoutactivevitamindinaustriaandswitzerlandtheobservationaltransitstudy AT pendlgunther managementofsecondaryhyperparathyroidismpracticepatternsandoutcomesofcinacalcettreatmentwithorwithoutactivevitamindinaustriaandswitzerlandtheobservationaltransitstudy AT hemetsbergermargit managementofsecondaryhyperparathyroidismpracticepatternsandoutcomesofcinacalcettreatmentwithorwithoutactivevitamindinaustriaandswitzerlandtheobservationaltransitstudy AT lhottakarl managementofsecondaryhyperparathyroidismpracticepatternsandoutcomesofcinacalcettreatmentwithorwithoutactivevitamindinaustriaandswitzerlandtheobservationaltransitstudy |